ATE42114T1 - Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung. - Google Patents

Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung.

Info

Publication number
ATE42114T1
ATE42114T1 AT83105116T AT83105116T ATE42114T1 AT E42114 T1 ATE42114 T1 AT E42114T1 AT 83105116 T AT83105116 T AT 83105116T AT 83105116 T AT83105116 T AT 83105116T AT E42114 T1 ATE42114 T1 AT E42114T1
Authority
AT
Austria
Prior art keywords
interferon
arg
production
sequence encoding
dna sequence
Prior art date
Application number
AT83105116T
Other languages
German (de)
English (en)
Inventor
Eva Dr Dworkin-Rastl
Marc-Bruce Dr Dworkin
Guenther Dr Mag Adolf
Peter Dr Meindl
Gerhard Prof Dr Bodo
Peter Dr Swetly
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE42114(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Application granted granted Critical
Publication of ATE42114T1 publication Critical patent/ATE42114T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT83105116T 1982-05-28 1983-05-24 Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung. ATE42114T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
EP83105116A EP0095702B1 (de) 1982-05-28 1983-05-24 Mikrobiologisch hergestelltes Interferon alpha2(Arg), DNA-Sequenz, die für dieses Interferon codiert, Mikroorganismen, die diese genetische Information enthalten, und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ATE42114T1 true ATE42114T1 (de) 1989-04-15

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83105116T ATE42114T1 (de) 1982-05-28 1983-05-24 Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung.

Country Status (22)

Country Link
US (1) US4820638A (enExample)
EP (1) EP0095702B1 (enExample)
JP (2) JPH0774238B2 (enExample)
KR (1) KR920006349B1 (enExample)
AT (1) ATE42114T1 (enExample)
AU (1) AU565479B2 (enExample)
DD (1) DD211359C4 (enExample)
DE (2) DE3220116A1 (enExample)
DK (1) DK164742C (enExample)
ES (2) ES522762A0 (enExample)
FI (1) FI82072C (enExample)
GR (1) GR79236B (enExample)
HK (1) HK112893A (enExample)
HU (1) HU196452B (enExample)
IL (1) IL68790A (enExample)
MX (1) MX9202815A (enExample)
NO (1) NO168538C (enExample)
NZ (1) NZ204384A (enExample)
SG (1) SG38692G (enExample)
SU (1) SU1346048A3 (enExample)
UA (1) UA8037A1 (enExample)
ZA (1) ZA833845B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IE54096B1 (en) * 1980-01-08 1989-06-21 Biogen Nv Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
HK112893A (en) 1993-10-29
NO168538C (no) 1992-03-04
NZ204384A (en) 1986-11-12
KR840004944A (ko) 1984-10-31
JPS5925689A (ja) 1984-02-09
ES8403522A1 (es) 1984-03-16
JPH0774238B2 (ja) 1995-08-09
NO831903L (no) 1983-11-29
IL68790A (en) 1991-06-10
US4820638A (en) 1989-04-11
JP2558422B2 (ja) 1996-11-27
DE3379591D1 (en) 1989-05-18
KR920006349B1 (ko) 1992-08-03
SG38692G (en) 1992-09-04
GR79236B (enExample) 1984-10-22
ES529360A0 (es) 1984-10-01
AU565479B2 (en) 1987-09-17
IL68790A0 (en) 1983-09-30
EP0095702A1 (de) 1983-12-07
DK239383D0 (da) 1983-05-27
ZA833845B (en) 1985-01-30
SU1346048A3 (ru) 1987-10-15
ES522762A0 (es) 1984-03-16
ES8500321A1 (es) 1984-10-01
FI82072B (fi) 1990-09-28
DK164742C (da) 1992-12-28
AU1504483A (en) 1983-12-01
JPH0678774A (ja) 1994-03-22
HU196452B (en) 1988-11-28
MX9202815A (es) 1992-06-30
NO168538B (no) 1991-11-25
FI82072C (fi) 1991-01-10
DE3220116A1 (de) 1983-12-01
EP0095702B1 (de) 1989-04-12
FI831818A0 (fi) 1983-05-23
DK164742B (da) 1992-08-10
UA8037A1 (uk) 1995-12-26
FI831818L (fi) 1983-11-29
DD211359A5 (de) 1984-07-11
DK239383A (da) 1983-11-29
DD211359C4 (de) 1986-09-24
DE3220116C2 (enExample) 1993-02-18

Similar Documents

Publication Publication Date Title
DE3379591D1 (en) Microbially prepared interferon alpha2(arg), dna sequence coding for said interferon, microorganisms containing this genetic information and process for their production
DE3177106D1 (en) Hybrid human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
HK49285A (en) Interferons and process for their preparation
ATE78868T1 (de) Alkalische protease, verfahren zur herstellung von hybridvektoren und genetisch transformierte mikroorganismen.
ES8306324A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ATE452979T1 (de) Herstellungsverfahren von 1,3-propandiol durch rekombinante organismen
KR830005350A (ko) 표면 결합체용 융합단백질 및 진핵 단백질 제조방법
ATE107698T1 (de) Herstellung und expression grosser struktureller gene.
EP0034307A3 (en) Microbiologically produced polypeptide having the amino acid sequence of human interferon, dna and plasmids coding for this sequence, microorganisms containing this genetic information and process for their production
AU6893587A (en) Recombinant dna sequences, vectors containing them and method for the use thereof
DE3678343D1 (de) Expressionskontrollsequenzen fuer gram-positive bakterien.
ES2142363T3 (es) Materiales y metodos para la hipersecrecion de aminoacidos.
AU3679389A (en) Regulatory region of gene which is turned on at late stage in microbial growth cycle
HUT39477A (en) New gene sequences, interferone i peptides determined by such sequences and microorganisms producing them
ATE44047T1 (de) Verfahren zur herstellung von interferonen.
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
EP0139501A3 (en) The manufacture and expression of genes for thaumatin
NZ241829A (en) Oxalate oxidase, genes encoding it, vectors and transformed plants
EP0072541A3 (en) Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
IT8119180A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi della proinsulina di primati, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
ES2115208T3 (es) Proteina de la superficie celular de brevibacterium lactofermentum.
JPS6471492A (en) Synthetic gene of cystatin b, corresponding recombinant plasmid and recombinant
KR950005990A (ko) 인간 인터류킨-4(human interleukin-4)의 효모에서의 발현
WO1995014774A3 (fr) Gene de resistance a la toxicite de la melasse, produits relies et leur utilisation pour analyser et ameliorer les microorganismes et les melasses

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee